It has been suggested that the weak IFN-dependent antiviral response in COVID-19 patients may be due to the failure of innate immune cells to mount an appropriate IFN-I response to infection, as evidenced by a reduced number and activity of plasmacytoid dendritic cells, the main source of IFNα during viral infections, in COVID-19 patients [49]. The gene discussed is IFNA1; the disease is COVID-19.